These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27153137)

  • 1. Bivalirudin versus unfractionated heparin for percutaneous coronary intervention with radial access: A meta-analysis of randomized trials.
    Mahmoud AN; Elgendy IY
    Int J Cardiol; 2016 Aug; 216():128-32. PubMed ID: 27153137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention.
    Shah R; Rogers KC; Matin K; Askari R; Rao SV
    Am Heart J; 2016 Jan; 171(1):14-24. PubMed ID: 26699596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalirudin versus heparin in women undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials.
    Saad M; Nairooz R; Rashed A; Abdelaziz HK; Mentias A; Abbott JD
    Cardiovasc Revasc Med; 2017 Sep; 18(6):418-424. PubMed ID: 28291727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
    Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
    BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.
    Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes of Bivalirudin Versus Heparin in Elderly Patients Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Meng S; Xu J; Guo L; Huang R
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):101-111. PubMed ID: 32100149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials.
    Lipinski MJ; Lhermusier T; Escarcega RO; Baker NC; Magalhães MA; Torguson R; Suddath WO; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2014; 15(6-7):315-22. PubMed ID: 25440505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivalirudin versus Heparin plus Glycoprotein IIb/IIIa Inhibitors in Women Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
    Xu H; Wang B; Yang J; Ma S; Xie X
    PLoS One; 2017; 12(1):e0169951. PubMed ID: 28095453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials.
    Bavry AA; Elgendy IY; Mahmoud A; Jadhav MP; Huo T
    PLoS One; 2015; 10(5):e0127832. PubMed ID: 26010682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Use of Bivalirudin and Radial Access in Acute Coronary Syndromes Is Not Superior to the Use of Either One Separately: Meta-Analysis of Randomized Controlled Trials.
    Mina GS; Gobrial GF; Modi K; Dominic P
    JACC Cardiovasc Interv; 2016 Aug; 9(15):1523-31. PubMed ID: 27491601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Zhang S; Gao W; Li H; Zou M; Sun S; Ba Y; Liu Y; Cheng G
    Int J Cardiol; 2016 Apr; 209():87-95. PubMed ID: 26882192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.
    Cavender MA; Sabatine MS
    Lancet; 2014 Aug; 384(9943):599-606. PubMed ID: 25131979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials.
    Cassese S; Byrne RA; Laugwitz KL; Schunkert H; Berger PB; Kastrati A
    EuroIntervention; 2015 Jun; 11(2):196-203. PubMed ID: 25102830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.
    Valgimigli M; Frigoli E; Leonardi S; Rothenbühler M; Gagnor A; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andò G; Repetto A; Limbruno U; Garbo R; Sganzerla P; Russo F; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Presbitero P; Santarelli A; Sardella G; Varbella F; Tresoldi S; de Cesare N; Rigattieri S; Zingarelli A; Tosi P; van 't Hof A; Boccuzzi G; Omerovic E; Sabaté M; Heg D; Jüni P; Vranckx P;
    N Engl J Med; 2015 Sep; 373(11):997-1009. PubMed ID: 26324049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction.
    Leibundgut G; Pache J; Schulz S; Berger PB; Ferenc M; Gick M; Mehilli J; Kastrati A; Neumann FJ
    J Interv Cardiol; 2013 Dec; 26(6):623-9. PubMed ID: 24118114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
    Bangalore S; Pencina MJ; Kleiman NS; Cohen DJ
    Circ Cardiovasc Interv; 2014 Jun; 7(3):365-73. PubMed ID: 24736878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials.
    Tarantini G; Brener SJ; Barioli A; Gratta A; Parodi G; Rossini R; Navarese EP; Niccoli G; Frigo AC; Musumeci G; Iliceto S; Stone GW
    Am Heart J; 2014 Mar; 167(3):401-412.e6. PubMed ID: 24576526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention.
    Barria Perez AE; Rao SV; Jolly SJ; Pancholy SB; Plourde G; Rimac G; Poirier Y; Costerousse O; Bertrand OF
    Am J Cardiol; 2016 Apr; 117(8):1256-66. PubMed ID: 26899489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.